DIET--ENDOCRINE STUDY OF BREAST AND PROSTATE CANCER

饮食——乳腺癌和前列腺癌的内分泌研究

• 批准号: 6072372
• 负责人: WENDY DEMARK-WAHNEFRIED
• 金额: $ 8.82万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6072372
• 关键词: basal metabolism; blood chemistry; body composition; body physical activity; body weight; breast neoplasms; caloric dietary content; cyclophosphamide; diet therapy; endocrinology; estradiol; female; fluorouracil; globulins; human subject; longitudinal human study; neoplasm /cancer chemotherapy; neoplasm /cancer education; nutrition related tag; prostate neoplasms; thermogenesis; weight control; women's health

Cancers of the prostate and breast constitute almost one-third of all cancers in the United States. These neoplasms, which have been characterized as hormonally-linked, are the leading cancers in American men and women. Despite obvious gender differences, these cancers share a substantial common ground [eg. similar rates of incidence, parallel epidemiologic relationships to various factors (high fat diet, obesity, etc.) and analogous proposed pathways of etiopathogenesis]. An academic award is sought in efforts to broaden the applicant's understanding of these hormone-related cancers. This effort is sponsored by primary mentor Barbara Rimer, Dr.PH, with planned experiences in relevant programs directed by James Iglehart, M.D., Eric Winer, M.D., Claude Hughes, M.D., Ph.D., and Cary Robertson, M.D. of Duke, and University of North Carolina's Paul Godley, M.D., Ph.D. and Boyd Switzer, Ph.D. The ultimate goal of the proposed program is to provide the applicant with a working knowledge-base in prostate and breast cancer, endocrinology and molecular biology/genetic regulation - a knowledge base that would complement her skills as a nutritionist and enable her to identify appropriate intermediate end points for nutrition intervention in these areas. This training will afford the applicant the springboard necessary for translational research in these areas and the opportunity to become an independent investigator in preventive oncology. A research project is a focal piece of the proposed training, and will permit the investigator to broaden and continue her interest in diet, body fat and its distribution, and their relationship to the continuum of neoplastic disease. The study is entitled "Exploration and Intervention in Weight Gain Associated with Adjuvant Chemotherapy for Breast Cancer." Weight gain is a common side effect in women receiving adjuvant chemotherapy for breast cancer - one that has been consistently reported throughout the past twenty years. For some therapies, gains of over 22 pounds are seen in one out of four women. This weight gain may be undesirable. First, it may have a profoundly negative psychosocial impact on a group of patients who may already have a compromised sense of self esteem. Second, recent findings suggest that weight gain during therapy is associated with decreased survival. Although weight gain during adjuvant chemotherapy for breast cancer is well-appreciated clinically, little research has been conducted to investigate the underlying mechanisms of this energy imbalance. Appropriate interventions cannot be developed until this is known. The specific aims of the proposed research are as follows: 1) to quantitate changes in energy intake and specific components of energy expenditure (ie. resting metabolic rate, diet-induced thermogenesis and physical activity) in 100 premenopausal breast cancer patients receiving adjuvant chemotherapy [six month regimens of cyclophosphamide + methotrexate + 5 fluorouracil (CMF) or cyclophosphamide + doxarubacin + 5 fluorouracil (CAF)] and 2) to use the findings of this proposed research to develop an appropriate intervention to prevent weight gain in this population. This research avenue has the potential to increase both the quantity and quality of life for breast cancer patients undergoing adjuvant chemotherapy, while making an overall contribution to our understanding of body weight and cancer.

前列腺和乳房的癌症几乎构成了所有人的三分之一 美国的癌症。这些肿瘤，已经 被荷尔蒙链接的特征是美国的主要癌症 男女。尽管性别差异明显，但这些癌症共享 实质性共同点[例如。相似的发射率，平行 与各种因素的流行病学关系（高脂饮食，肥胖， 等）和类似的疗法发生途径]。学者 寻求奖励以扩大申请人对 这些与激素有关的癌症。这项工作由主要导师赞助 Barbara Rimer，博士，在相关计划中有计划的经验 由M.D. James Iglehart执导 博士学位和杜克大学的Cary Robertson和North University of North 卡罗来纳州的保罗·戈德利（Paul Godley），医学博士，博士和博伊德·斯威泽（Boyd Switzer）博士最终 拟议计划的目标是为申请人提供工作 前列腺和乳腺癌，内分泌学和分子的知识碱 生物学/遗传调节 - 一个可以补充她的知识基础 作为营养学家的技能，使她能够确定适当的 在这些地区营养干预的中间终点。这 培训将为申请人提供申请人的跳板 这些领域的翻译研究，并有机会成为 预防肿瘤学的独立研究者。 研究项目是拟议培训的重点，将 允许研究人员拓宽并继续对饮食，身体感兴趣 脂肪及其分布以及它们与连续性的关系 肿瘤疾病。该研究的标题为“探索和干预 体重增加与乳腺癌的辅助化疗相关。” 体重增加是接受佐剂的妇女的常见副作用 乳腺癌的化学疗法 - 一直报道 在过去的二十年中。对于某些疗法，收益超过22 四分之一的女人中有一个体重。这种体重增加可能是 不希望的。 首先，它可能产生深远的负面社会心理影响 在一群可能已经受到威胁的自我意识的患者身上 尊重。第二，最近的发现表明，治疗期间的体重增加是 与生存降低有关。虽然在佐剂期间体重增加 乳腺癌的化学疗法在临床上是充分欣赏的，很少 已经进行了研究以研究的基本机制 这种能量不平衡。直到 这是已知的。 拟议研究的具体目的如下：1） 量化能量摄入的变化和能量的特定成分 支出（即静息代谢率，饮食引起的热生成和 体育锻炼）在100名月胸膜前乳腺癌患者中接受 辅助化疗[环磷酰胺 +六个月的方案 甲氨蝶呤 + 5氟尿嘧啶（CMF）或环磷酰胺 + doxarubacin + 5 氟尿嘧啶（CAF）]和2）使用此拟议研究的发现 开发适当的干预措施以防止体重增加 人口。该研究途径有可能增加 乳腺癌患者的数量和生活质量 辅助化疗，同时为我们的总体贡献 了解体重和癌症。

项目成果

Effect of mammalian lignans on the growth of prostate cancer cell lines.

• 发表时间: 2001-11
• 期刊: Anticancer research
• 影响因子: 2
• 作者: Xuehua Lin;B. Switzer;W. Demark-Wahnefried

Preventing sarcopenic obesity among breast cancer patients who receive adjuvant chemotherapy: results of a feasibility study.

预防接受辅助化疗的乳腺癌患者出现肌肉减少性肥胖：可行性研究的结果。

• 发表时间: 2002
• 期刊: Clinical exercise physiology
• 作者: Demark-Wahnefried,Wendy;Kenyon,AnneJacobs;Eberle,Pamela;Skye,Ann;Kraus,WilliamE
• 通讯作者: Kraus,WilliamE